Bausch Health Companies Inc. (NYSE:BHC) Receives $7.42 Consensus Target Price from Brokerages

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $7.42.

A number of research analysts have recently commented on the stock. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada dropped their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th.

Bausch Health Companies Price Performance

BHC traded down $0.08 on Friday, hitting $7.14. 716,186 shares of the stock were exchanged, compared to its average volume of 2,995,136. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The business has a 50-day moving average of $7.31 and a two-hundred day moving average of $7.63. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of -59.45, a PEG ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Equities research analysts expect that Bausch Health Companies will post 4.41 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Bausch Health Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mountain Hill Investment Partners Corp. acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $56,000. Bank of Nova Scotia acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $83,000. One68 Global Capital LLC acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $90,000. Balyasny Asset Management L.P. acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $97,000. Finally, Alpine Global Management LLC acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $114,000. Institutional investors and hedge funds own 78.65% of the company's stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.